Biotech companies have outperformed the general market -- and there are plenty of reasons to remain optimistic.
News & Analysis: Biogen
We examine three biotech companies' past performances and future outlooks.
The biotech popped 30% after the extremely unusual revival of an Alzheimer's treatment that had looked like a failure at first.
Competitors make headway against Teva Pharmaceutical's top seller, and Biogen's hemophilia drugs become Bioverativ. Here's what you should know.
The Industry Focus team compares Biogen's and Celgene's current valuations and considers what might be in store for Gilead Sciences now that its new hepatitis C drug is approved.
What cancer drug companies came out ahead at this weekend's ASCO conference and a closer look at Biogen's recent disappointment.
GlaxoSmithKline takes on Pfizer, and Biogen battles Celgene in this healthcare edition of Industry Focus.